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Abstract: Taking into account the pharmacological relevance of heterocycle-fused natural steroids,
the objective of the current study was to develop a multistep reaction sequence for the efficient
synthesis of novel D-ring-condensed 5-amino-1-arylpyrazoles from dehydroepiandrosterone (DHEA).
A condensation reaction of 16-formyl-DHEA with hydroxylamine afforded the corresponding oxime,
which was demonstrated to be stable in one of its cyclic isoxazoline forms due to possible ring-chain
tautomerism. The subsequent base-induced dehydration to a diastereomeric β-ketonitrile, followed
by microwave-assisted heterocyclization with different arylhydrazines led to the desired pyrazoles.
The generally good yields of the products depended slightly on the electronic character of the
substituent present on the aromatic ring of the reagent. The proton dissociation processes of the
DHEA-derived heterocycles were investigated in aqueous solution by UV-visible spectrophotometric
titrations to reveal their actual chemical forms at physiological pH. The determined pKa values
attributed to the pyrazole NH+ moiety were low (1.8–4.0) and varied by the different substituents of
the benzene ring. The antiproliferative effects of the structurally similar compounds were screened
in vitro on human cancer cells (namely on HeLa, U2Os, MCF-7, PC-3, and A549), along with a
noncancerous cell line (MRC-5). The IC50 values of the most active derivative were determined on all
cell lines.
Keywords: steroid; heterocycles; aminopyrazole; microwave; organic synthesis; proton dissociation;
anticancer activity
1. Introduction
Structural modification of natural sex hormones by the introduction of various heterocyclic
moieties may alter the physicochemical properties and the pharmacokinetic behavior, as well as
the biological activity of the parent compound [1]. Continuous interest in steroid derivatives with
nitrogen-containing heterorings condensed with, or connected to ring D of the sterane framework
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arises from the significant pharmacological potential of these molecules [2]. Several studies have
demonstrated that steroidal aza-heterocyclic derivatives can be effective in the prevention and treatment
of hormone-dependent cancers. They can also act as cytotoxic agents through hormone-independent
mechanisms of action [3]. Heteroaromatic five-membered pyrazoles containing two adjacent nitrogen
atoms have received considerable attention thanks to their facile synthetic availability and their
usefulness as intermediates for the preparation of various biologically active compounds, metal
complexes, and functional materials [4,5]. Over the past decades, numerous pyrazoles in the
androstane series and their partially saturated pyrazoline analogs have been reported to exhibit a
more marked antitumor activity rather than their expected hormonal effect (Figure 1) [6–13]. Amongst
functionalized pyrazoles, 5-aminopyrazoles have been widely investigated as biologically active
agents [14] and as useful binucleophilic precursors for fused pyrazoloazines of medicinal interest [15].
Moreover, 5-amino-1-arylpyrazoles, which are usually obtained by the reaction of β-ketonitriles or
malonitrile derivatives with arylhydrazines, constitute the main structural motif of a vast number of
bioactive compounds with kinase-inhibitory, anticancer, anti-infective, anti-inflammatory, or other
effects [16]. Although β-ketonitriles are also suitable starting materials for the synthesis of other
5-amino-substituted 1,2-azoles, such as isoxazoles [17] or isothiazoles [18], previous research has shown
that the incorporation of a N,N-heterocyclic ring into the sterane backbone is much more beneficial
in terms of anticancer activity. As concerns the synthetic methodologies, a number of reactions have
been reported so far for the synthesis of different steroid-fused heterocycles under microwave (MW)
irradiation due to the advantageous characteristics of this approach, such as enhanced reaction rates,
manipulative simplicity, and high product yields [19,20].
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In view of the marked cytotoxic activity of some androstane-based pyrazol(in)es [6–13], and the
pharmacological relevance of drugs containing a 5-amino-1-arylpyrazole moiety [16], the aim of the
present study was to introduce such heterocyclic subunit fused to ring D of dehydroepiandrosterone
(DHEA) to obtain a set of compounds suitable for further investigations. To our knowledge,
steroidal 5-aminopyrazoles have not been synthesized and studied so far. The heterocyclizations
were designed and performed from a DHEA-derived β-ketonitrile and various arylhydrazines,
respectively, under pre-optimized M -assisted reaction conditions. Proton dissociation processes
of the heterocycles and the dependence of the determined pKa values on the electron demand
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of the aryl substituents were also investigated. The cytotoxicity of the molecules was screened
in vitro on different human cancer cell lines, along with a noncancerous cell line by the colorimetric
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay [21]. In addition, based on
the screen, one compound—showing the highest efficacy to inhibit the proliferation of various cancer
cells—was selected and subjected to additional in vitro tests in order to determine its IC50 values on all
tested cell lines.
2. Materials and Methods
2.1. General
General information has been previously reported in detail [22]. In brief, the purchase sources
of chemicals, which were used without purification are: Sigma-Aldrich Corporation, St. Louis, MO,
USA; TCI, Tokyo, Japan; and Alfa Aesar, Haverhill, MA, USA. MW-reactor: CEM Discover SP (CEM
Corporation, Matthews, NC, USA), maximum power (dynamic control program): 200 W. Thin-layer
chromatography (TLC) plates (0.25 mm thick): Kieselgel-G (Si 254 F, Merck KGaA, Darmstadt,
Germany). Column chromatography: silica gel 60, 40–63 µm (Merck KGaA, Darmstadt, Germany).
NMR instrument: Bruker DRX 500 (Bruker, Billerica, MA, USA). NMR spectra (at 298 K) of all
compounds were recorded in DMSO-d6 using the residual solvent signal as reference. Coupling
constants (J) are given in Hz and chemical shifts in ppm (δ scale). In the 1H NMR spectra the
multiplicities of the signals are reported as a singlet (s), a broad singlet (bs), a doublet (d), a double
doublet (dd), or a multiplet (m). 1H-decoupled 13C NMR spectra were recorded. For the determination
of multiplicities, the J-MOD pulse sequence was applied. Melting point (Mp) apparatus: SRS Optimelt
digital device (Stanford Research Systems Inc., Sunnyvale, CA, USA); Elementary analysis: PerkinElmer
CHN analyzer model 2400 (PerkinElmer Inc., Waltham, MA, USA). Automated flow injection analyses:
HPLC/MSD system. System accessories: a micro-well plate autoinjector, an Agilent 1100 micro vacuum
degasser (Agilent Technologies, Santa Clara, CA, USA), a quaternary pump, and a 1946A MSD with
an electrospray ion source (ESI) operated in positive ion mode. ESI parameters: nebulizing gas N2
(at 35 psi); drying gas N2 (at 350 ◦C, 12 L/min); capillary voltage: 3000 V; fragmentor voltage: 70 V.
The MSD was operated with a mass range of m/z 60–620 in scan mode. Samples (0.2 µL) were injected
directly into the solvent flow (0.3 mL/min) of CH3CN/H2O = 70:30 (v/v) with the simultaneous addition
of 0.1% formic acid with an automated needle wash. Agilent LC/MSD Chemstation (C.01.08, Agilent
Technologies Inc., Santa Clara, CA, USA) was used as software to control the system.
2.2. Synthetic Procedures
2.2.1. Characterization of 2′-Isoxazolino [4′.5′: 16.17] Androst-5-en-3β,17-diol (2)
Synthesis of compound 2 was performed from 16-formyl DHEA (1) according to literature
method [23] with some modifications. Mp 258–260 ◦C (white solid); Rf = 0.18 (EtOAc/CH2Cl2 = 20:80
v/v). Anal. Calcd. for C20H29NO3 (331.46): C, 72.47; H, 8.82. Found: C, 72.60; H, 8.92. 1H NMR
(DMSO-d6, 500 MHz): δ 0.82–0.85 (4H, m, 1H and s, 3H, 18-H3), 0.94 (s, 3H, 19-H3), 0.98 (m, 2H),
1.30–1.68 (overlapping m, 10H), 1.76 (m, 1H), 1.89 (m, 1H), 2.04–2.16 (overlapping m, 2H), 3.12 (d, 1H,
J = 10.2 Hz), 3.25 (m, 1H, 3-H), 4.61 (d, 1H, J = 4.5 Hz, 3-OH), 5.24 (d, 1H, J = 4.6 Hz, 6-H), 6.63 (s, 1H,
17-OH), 7.29 (d, 1H, J = 1.7 Hz, 3′-H); 13C NMR (DMSO-d6, 125 MHz): δ 15.7 (C-18), 19.1 (C-19), 19.9
(CH2), 29.0 (CH2), 30.3 (CH), 31.1 (CH2), 31.2 (C-16), 31.4 (CH2), 36.2 (C-10), 36.9 (CH2), 42.2 (C-13), 46.1
(CH2), 49.4 (2C, 2 × CH), 54.9 (CH), 69.9 (C-3), 116.5 (C-17), 120.1 (C-6), 141.3 (C-5), 150.4 (C-3′); ESI-MS
332 [M + H]+.
2.2.2. Synthesis of 16-Cyano-3β-Hydroxy-Androst-5-en-17-One (3)
To a solution of compound 2 (2 g, 6.03 mmol) in MeOH (20 mL), KOH (1.68 g, 30 mmol), also
dissolved in MeOH (10 mL) was added. After stirring the mixture at room temperature for 30 min,
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it was poured into water (100 mL) and neutralized with diluted HCl. The precipitate was filtered
off and dried. Column chromatographic purification of the crude product with EtOAc/CH2Cl2 =
10:90 provided an epimeric mixture (16β-CN (a)/16α-CN (b) = 2:1) of 3 as a white solid (1.64 g, 87%).
Rf = 0.48. Anal. Calcd. for C20H27NO2 (313.44): C, 76.64; H, 8.68. Found: C, 76.55; H, 8.59. 1H NMR
(DMSO-d6, 500 MHz): δ 0.88 (s, 18-H3, b), 0.90 (s, 18-H3, a), 0.96 (s, 19-H3, a + b), 3.26 (m, 3-H, a + b),
3.78 (dd, J = 9.3 Hz, J = 9.3 Hz, 16-H, a), 4.36 (d, J = 8.7 Hz, 16-H, b), 4.63 (d, J = 4.4 Hz 3-OH, a + b),
5.30 (m, 6-H, a + b); 13C NMR (DMSO-d6, 125 MHz): δ 12.8 (C-18, b), 13.7 (C-18, a), 19.1 (C-19, a + b),
19.7 (CH2, a + b), 26.9 (CH2, b), 27.5 (CH2, a), 29.7 (CH2, b), 30.1 (CH2, a), 30.4 (CH, a), 30.9 (CH, b), 30.9
(CH2, a), 31.1 (CH2, b), 31.4 (CH2, a + b), 35.3 (CH, b), 36.2 (C-10, a + b), 36.3 (CH, a), 36.8 (CH2, a + b),
42.1 (C-13, a + b), 47.0 (CH2, b), 47.6 (CH2, a), 48.3 (CH, a + b), 49.2 (CH, b), 49.5 (CH, a), 69.9 (C-3, a +
b), 118.4 (CN, a), 118.6 (CN, a), 119.7 (C-6, a), 119.8 (C-6, b), 141.4 (C-5, b), 141.5 (C-5, a), 209.3 (C-17, b),
209.5 (C-17, a); ESI-MS 314 [M + H]+.
2.2.3. General Procedure for The Synthesis of D-Ring-Condensed 5-Amino-1-Arylpyrazoles (6a–h)
Under MW Irradiation
To a solution of 16-cyano-3β-hydroxy-androst-5-en-17-one (3, 157 mg, 0.5 mmol) in EtOH (5 mL),
arylhydrazine hydrochloride (5a–h, 1.5 equiv., 0.75 mmol) and NaOAc (61.5 mg, 1.5 equivalent) were
added, and the mixture was MW-irradiated at 120 ◦C for 10 min in a closed vessel. After completion of
the reaction, the mixture was poured into water (20 mL), saturated with NH4Cl and the precipitate
formed was filtered off. Column chromatographic purification of the crude product was performed
with EtOAc/CH2Cl2 = 20:80 as mobile phase.
5′-Amino-1′-Phenylpyrazolo[3′,4′:17,16]Androst-5-en-3β-ol (6a)
Phenylhydrazine hydrochloride (5a, 108 mg) was used as described in the general procedure. Yield:
182 mg (90%, white solid); Mp 258–260 ◦C; Rf = 0.23 (EtOAc/CH2Cl2 = 20:80 v/v). Anal. Calcd. for
C26H33N3O (403.57): C, 77.38; H, 8.24. Found: C, 77.27; H, 8.13. 1H NMR (DMSO-d6, 500 MHz): δ 0.97
(s, 3H, 18-H3), 1.01 (s, 3H, 19-H3 and m, 2H), 1.37 (m, 1H), 1.51–1.81 (overlapping m, 8H), 1.96–2.20
(overlapping m, 5H), 2.42 (dd, 1H, J = 13.3 Hz, J = 5.0 Hz, one of 15-H2), 3.28 (m, 1H, 3-H), 4.62 (d, 1H,
J = 3.0 Hz, 3-OH), 5.09 (s, 2H, 5′-NH2), 5.33 (d, 1H, J = 4.5 Hz, 6-H), 7.21 (m, 1H, 4”-H), 7.41 (m, 2H,
3”-H and 5”-H), 7.54 (d, 2H, J = 7.7 Hz, 2”-H and 6”-H); 13C NMR (DMSO-d6, 125 MHz): δ 18.0 (C-18),
19.1 (C-19), 20.2 (CH2), 23.6 (CH2), 30.4 (CH), 30.9 (CH2), 31.5 (CH2), 33.5 (CH2), 36.3 (C-10), 36.8 (CH2),
40.2 (C-13), 42.3 (CH2), 50.1 (CH), 61.2 (CH), 70.0 (C-3), 104.1 (C-16), 120.2 (C-6), 122.2 (2C, C-2” and
C-6”), 125.0 (C-4”), 128.8 (2C, C-3” and C-5”), 140.3, 140.6 and 140.7 (C-5, C-5′ and C-1”), 168.4 (C-17);
ESI-MS 404 [M + H]+.
5′-Amino-1′-4”-Tolylpyrazolo[3′,4′:17,16]Androst-5-en-3β-ol (6b)
4-Tolylhydrazine hydrochloride (5b, 119 mg) was used as described in the general procedure. Yield:
186 mg (89%, white solid); Mp 267–269 ◦C; Rf = 0.26 (EtOAc/CH2Cl2 = 20:80 v/v). Anal. Calcd. for
C27H35N3O (417.60): C, 77.66; H, 8.45. Found: C, 77.47; H, 8.32. 1H NMR (DMSO-d6, 500 MHz): δ 0.95
(s, 3H, 18-H3), 1.01 (s, 3H, 19-H3 and m, 2H), 1.37 (m, 1H), 1.49-1.80 (overlapping m, 8H), 1.98-2.19
(overlapping m, 5H), 2.31 (s, 3H, 4”-CH3), 2.40 (dd, 1H, J = 13.3 Hz, J = 4.7 Hz, one of 15-H2), 3.27 (m,
1H, 3-H), 4.62 (d, 1H, J = 4.5 Hz, 3-OH), 5.03 (s, 2H, 5′-NH2), 5.32 (d, 1H, J = 4.1 Hz, 6-H), 7.21 (d, 2H,
J = 8.2 Hz, 3”-H and 5”-H), 7.40 (d, 2H, J = 8.2 Hz, 2”-H and 6”-H); 13C NMR (DMSO-d6, 125 MHz): δ
18.0 (C-18), 19.1 (C-19), 20.2 (CH2), 20.5 (4”-CH3), 23.6 (CH2), 30.4 (CH), 30.9 (CH2), 31.5 (CH2), 33.6
(CH2), 36.4 (C-10), 36.9 (CH2), 40.2 (C-13), 42.3 (CH2), 50.1 (CH), 61.2 (CH), 70.0 (C-3), 103.8 (C-16),
120.2 (C-6), 122.4 (2C, C-2” and C-6”), 129.3 (2C, C-3” and C-5”), 134.3 (C-4”), 137.9 (C-1”), 140.5 (C-5),
141.6 (C-5′), 168.1 (C-17); ESI-MS 418 [M + H]+.
5′-Amino-1′-(4”-Methoxy)phenylpyrazolo[3′,4′:17,16]Androst-5-en-3β-ol (6c)
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4-Methoxy-phenylhydrazine hydrochloride (5c, 131 mg) was used as described in the general procedure.
Yield: 199 mg (92%, white solid); Mp 209–211 ◦C; Rf = 0.17 (EtOAc/CH2Cl2 = 20:80 v/v). Anal. Calcd.
for C27H35N3O2 (433.60): C, 74.79; H, 8.14. Found: C, 74.65; H, 8.02. 1H NMR (DMSO-d6, 500 MHz): δ
0.95 (s, 3H, 18-H3), 1.01 (s, 3H, 19-H3 and m, 2H), 1.37 (m, 1H), 1.49–1.80 (overlapping m, 8H), 1.97–2.20
(overlapping m, 5H), 2.40 (dd, 1H, J = 13.2 Hz, J = 4.7 Hz, one of 15-H2), 3.27 (m, 1H, 3-H), 3.77 (s, 3H,
4”-OMe), 4.63 (d, 1H, J = 4.5 Hz, 3-OH), 4.96 (s, 2H, 5′-NH2), 5.32 (m, 1H, 6-H), 6.96 (d, 2H, J = 9,0 Hz,
3”-H and 5”-H), 7.40 (d, 2H, J = 9.0 Hz, 2”-H and 6”-H); 13C NMR (DMSO-d6, 125 MHz): δ 18.1 (C-18),
19.1 (C-19), 20.2 (CH2), 23.6 (CH2), 30.4 (CH), 30.9 (CH2), 31.5 (CH2), 33.6 (CH2), 36.4 (C-10), 36.9 (CH2),
40.2 (C-13), 42.3 (CH2), 50.1 (CH), 55,3 (4”-OMe), 61.3 (CH), 70.0 (C-3), 103.4 (C-16), 114.0 (2C, C-2” and
C-6”), 120.2 (C-6), 124.4 (2C, C-3” and C-5”), 133.4 (C-1”), 140.4 (C-5), 141.6 (C-5′), 156.9 (C-4”), 167.8
(C-17); ESI-MS 434 [M + H]+.
5′-Amino-1′-(4”-Fluoro)phenylpyrazolo[3′,4′:17,16]Androst-5-en-3β-ol (6d)
4-Fluoro-phenylhydrazine hydrochloride (5d, 122 mg) was used as described in the general procedure.
Yield: 198 mg (94%, white solid); Mp 278–280 ◦C; Rf = 0.35 (EtOAc/CH2Cl2 = 20:80 v/v). Anal. Calcd.
for C26H32FN3O (421.56): C, 74.08; H, 7.65. Found: C, 73.95; H, 8.73. 1H NMR (DMSO-d6, 500 MHz): δ
0.96 (s, 3H, 18-H3), 1.01 (s, 3H, 19-H3 and m, 2H), 1.37 (m, 1H), 1.50–1.80 (overlapping m, 8H), 1.97–2.20
(overlapping m, 5H), 2.41 (dd, 1H, J = 13.3 Hz, J = 4.7 Hz, one of 15-H2), 3.27 (m, 1H, 3-H), 4.63 (d, 1H,
J = 4.5 Hz, 3-OH), 5.11 (s, 2H, 5′-NH2), 5.32 (m, 1H, 6-H), 7.23 (dd, 2H, J = 8.8 Hz, J = 8.8 Hz, 3”-H and
5”-H), 7.54 (dd, 2H, J = 8.8 Hz, J = 5.0 Hz, 2”-H and 6”-H); 13C NMR (DMSO-d6, 125 MHz): δ 18.0
(C-18), 19.1 (C-19), 20.2 (CH2), 23.6 (CH2), 30.4 (CH), 30.9 (CH2), 31.5 (CH2), 33.5 (CH2), 36.4 (C-10),
36.9 (CH2), 40.3 (C-13), 42.3 (CH2), 50.1 (CH), 61.2 (CH), 70.0 (C-3), 104.1 (C-16), 115.5 (d, 2C, J = 22.5
Hz, C-3” and C-5”), 120.2 (C-6), 124.5 (d, 2C, J = 8.4 Hz, C-2” and C-6”), 136.7 (d, J = 2,5 Hz, C-1”),
140.8 (C-5), 141.6 (C-5′), 159.6 (d, J = 241.9 Hz, C-4”), 168.4 (C-17); ESI-MS 422 [M + H]+.
5′-Amino-1′-(4”-Chloro)phenylpyrazolo[3′,4′:17,16]Androst-5-en-3β-ol (6e)
4-Chloro-phenylhydrazine hydrochloride (5e, 134 mg) was used as described in the general procedure.
Yield: 175 mg (80%, white solid); Mp 299–301 ◦C; Rf = 0.32 (EtOAc/CH2Cl2 = 20:80 v/v). Anal. Calcd.
for C26H32ClN3O (438.01): C, 71.30; H, 7.36. Found: C, 71.45; H, 7.22. 1H NMR (DMSO-d6, 500 MHz): δ
0.96 (s, 3H, 18-H3), 1.01 (s, 3H, 19-H3 and m, 2H), 1,36 (m, 1H), 1,50–1,80 (overlapping m, 8H), 1,98–2,19
(overlapping m, 5H), 2.41 (dd, 1H, J = 13.4 Hz, J = 4.5 Hz, one of 15-H2), 3.27 (m, 1H, 3-H), 4.63 (d,
1H, J = 4.5 Hz, 3-OH), 5.19 (s, 2H, 5′-NH2), 5.32 (m, 1H, 6-H), 7.44 (d, 2H, J = 8.8 Hz, 3”-H and 5”-H),
7.58 (d, 2H, J = 8.8 Hz, 2”-H and 6”-H); 13C NMR (DMSO-d6, 125 MHz): δ 17.9 (C-18), 19.1 (C-19), 20.2
(CH2), 23.6 (CH2), 30.4 (CH), 30.9 (CH2), 31.5 (CH2), 33.5 (CH2), 36.4 (C-10), 36.8 (CH2), 40.3 (C-13), 42.3
(CH2), 50.0 (CH), 61.1 (CH), 70.0 (C-3), 104.5 (C-16), 120.2 (C-6), 123.6 (2C, C-2” and C-6”), 128.8 (2C,
C-3” and C-5”), 128.9 (C-4”), 139.2 (C-1”), 140.9 (C-5), 141.6 (C-5′), 168.8 (C-17); ESI-MS 439 [M + H]+.
5′-Amino-1′-(4”-Bromo)phenylpyrazolo[3′,4′:17,16]Androst-5-en-3β-ol (6f)
4-Bromo-phenylhydrazine hydrochloride (5f, 168 mg) was used as described in the general procedure.
Yield: 202 mg (84%, white solid); Mp > 210 ◦C (decomp.); Rf = 0.39 (EtOAc/CH2Cl2 = 20:80 v/v). Anal.
Calcd. for C26H32BrN3O (482.47): C, 64.73; H, 6.69. Found: C, 64.84; H, 6.81. 1H NMR (DMSO-d6, 500
MHz): δ 0.96 (s, 3H, 18-H3), 1.01 (s, 3H, 19-H3 and m, 2H), 1.35 (m, 1H), 1.49–1.79 (overlapping m, 8H),
1.97–2.18 (overlapping m, 5H), 2.41 (dd, 1H, J = 13.3 Hz, J = 4.5 Hz, one of 15-H2), 3.26 (m, 1H, 3-H),
4,63 (bs, 1H, 3-OH), 5,22 (bs, 2H, 5′-NH2), 5.32 (m, 1H, 6-H), 7.52 (d, 2H, J = 8.8 Hz) and 7.58 (d, 2H, J =
8.8 Hz): 3”-H, 5”-H and 2”-H, 6”-H; 13C NMR (DMSO-d6, 125 MHz): δ 17.9 (C-18), 19.2 (C-19), 20.2
(CH2), 23.6 (CH2), 30.4 (CH), 30.9 (CH2), 31.5 (CH2), 33.4 (CH2), 36.4 (C-10), 36.8 (CH2), 40.3 (C-13), 42.3
(CH2), 50.0 (CH), 61.1 (CH), 70.0 (C-3), 104.6 (C-16), 117.2 (C-4”), 120.2 (C-6), 124.0 (2C, C-2” and C-6”),
131.7 (2C, C-3” and C-5”), 139.6 (C-1”), 141.0 (C-5), 141.6 (C-5′), 168.9 (C-17); ESI-MS 483 [M + H]+.
5′-Amino-1′-(4”-Cyano)phenylpyrazolo[3′,4′:17,16]Androst-5-en-3β-ol (6g)
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4-Cyano-phenylhydrazine hydrochloride (5g, 127 mg) was used as described in the general procedure.
Yield: 182 mg (85%, white solid); Mp 293–295 ◦C; Rf = 0.34 (EtOAc/CH2Cl2 = 20:80 v/v). Anal. Calcd.
for C27H32N4O (428.58): C, 75.67; H, 7.53. Found: C, 75.75; H, 7.39. 1H NMR (DMSO-d6, 500 MHz): δ
0.97 (s, 3H, 18-H3), 1.01 (s, 3H, 19-H3 and m, 2H), 1.36 (m, 1H), 1.51–1.79 (overlapping m, 8H), 1.97–2.20
(overlapping m, 5H), 2.43 (dd, 1H, J = 13.6 Hz, J = 4.7 Hz, one of 15-H2), 3.27 (m, 1H, 3-H), 4.63 (d,
1H, J = 4.5 Hz, 3-OH), 5.32 (m, 1H, 6-H), 5.40 (s, 2H, 5′-NH2), 7.82 (d, 2H, J = 8.7 Hz, 3”-H and 5”-H),
7.85 (d, 2H, J = 8.7 Hz, 2”-H and 6”-H); 13C NMR (DMSO-d6, 125 MHz): δ 17.8 (C-18), 19.1 (C-19), 20.1
(CH2), 23.5 (CH2), 30.4 (CH), 30.8 (CH2), 31.5 (CH2), 33.3 (CH2), 36.3 (C-10), 36.8 (CH2), 40.3 (C-13), 42.3
(CH2), 50.0 (CH), 61.0 (CH), 70.0 (C-3), 105.7 and 106.2: C-4” and C-16, 118.9 (4”-CN), 120.1 (C-6), 121.2
(2C, C-2” and C-6”), 133.2 (2C, C-3” and C-5”), 141.6 and 141.7: C-1” and C-5, 144.2 (C-5′), 170.1 (C-17);
ESI-MS 429 [M + H]+.
5′-Amino-1′-(4”-Nitro)phenylpyrazolo[3′,4′:17,16]Androst-5-en-3β-ol (6h)
4-Nitro-phenylhydrazine hydrochloride (5h, 127 mg) was used as described in the general procedure.
Yield: 117 mg (52%, Table 1, entry 82a) or 197 mg (88%, Table 1, entry 82b), (yellow solid); Mp 242–244
◦C; Rf = 0.32 (EtOAc/CH2Cl2 = 20:80 v/v). Anal. Calcd. for C26H32N4O3 (448.57): C, 69.62; H, 7.19.
Found: C, 69.49; H, 7.05. 1H NMR (DMSO-d6, 500 MHz): δ 0.98 (s, 3H, 18-H3), 1.01 (s, 3H, 19-H3
and m, 2H), 1.37 (m, 1H), 1.51–1.80 (overlapping m, 8H), 1.99–2.20 (overlapping m, 5H), 2.43 (dd, 1H,
J = 13.6 Hz, J = 4.6 Hz, one of 15-H2), 3.27 (m, 1H, 3-H), 4.63 (d, 1H, J = 4.5 Hz, 3-OH), 5.31 (m, 1H,
6-H), 5.49 (s, 2H, 5′-NH2), 7.92 (d, 2H, J = 9.2 Hz, 2”-H and 6”-H), 8.26 (d, 2H, J = 9.2 Hz, 3”-H and
5”-H); 13C NMR (DMSO-d6, 125 MHz): δ 17.8 (C-18), 19.1 (C-19), 20.2 (CH2), 23.5 (CH2), 30.4 (CH), 30.8
(CH2), 31.5 (CH2), 33.2 (CH2), 36.3 (C-10), 36.8 (CH2), 40.4 (C-13), 42.3 (CH2), 50.0 (CH), 60.9 (CH), 70.0
(C-3), 106.1 (C-16), 120.2 (C-6), 120.7 (2C, C-2” and C-6”), 124.8 (2C, C-3” and C-5”), 141.6 (C-5), 142.0,
143.0 and 146.0 (C-1”, C-4” and C-5′), 170.7 (C-17); ESI-MS 449 [M + H]+.
2.3. UV Spectrophotometric Titrations
Stock solutions of the tested compounds were prepared in EtOH at 100 µM concentration.
UV-visible spectra were recorded for compounds 6a-h in order to determine proton dissociation
constants (pKa) in the pH range 1.8–10. The compounds had absorption only in the UV range.
Measurements were accomplished at a constant ionic strength (0.10 M KCl) and at 25.0 ± 0.1 ◦C in
aqueous phase (with 1% (v/v) EtOH). For the titrations, a carbonate-free KOH solution (0.10 M) was
used, the concentration of which was determined by pH-potentiometric titrations. The initial volume of
the samples was 10.0 mL and the spectrophotometric titrations were performed on samples containing
10 µM of tested compounds. Purified argon was bubbled through the samples for deoxygenation circa
10 min prior the measurements. The UV spectra of the individual species in the various protonation
states and the proton dissociation constants were calculated with the computer program PSEQUAD [24].
Experimental titration data measured in the absence of any precipitate in the solution (pH = 1.8–5
(or 3.5 in case of 6h)) were used for the calculations. In the interval 200–800 nm, a diode array
spectrophotometer (Hewlett Packard 8452A) was applied to record the spectra. The length of the path
was 2 cm.
Attempts to determine the distribution coefficients (D7.4) and permeability values have been made
in n-octanol/buffered aqueous solution by using the traditional shake-flask method at pH 7.40 (20 mM
phosphate buffer, 0.10 M KCl), as described earlier [25], and by the PAMPA method using a Corning
Gentest pre-coated PAMPA Plate System [26], respectively.
2.4. MTT Cell Viability Assay
All the test compounds were dissolved in DMSO (cell culture grade, Molar Chemicals, Halásztelek,
Hungary) to obtain a stock solution of 10 mM final concentration, and stored at 4 ◦C, light protected,
until further use. Antiproliferative activity of the synthesized steroids was assessed by MTT reduction
assay [21] on human MCF-7 breast adenocarcinoma, PC-3 prostate cancer, A549 lung carcinoma,
Appl. Sci. 2020, 10, 229 7 of 13
HeLa cervical adenocarcinoma, U2Os osteosarcoma cell lines, and on MRC-5 human noncancerous
fibroblasts. A total 5000 cells/well were seeded into 96 well plates and 24 h later cells were exposed to
the test compounds in 5 µM concentration for 72 h. Cells receiving no treatment were used as control
throughout the experiments. To obtain IC50 values of the selected compound on various cancerous
and noncancerous lines, cells were seeded again in 5000 cells/well density in 96 well plates and treated
with the compound in 1, 3, 5, 7, and 9 µM concentrations or cisplatin in 20, 40, 80, 160, and 330 nM
concentrations for 72 h. After the treatments, cells were washed using phosphate-buffered saline
(PBS) and incubated with 0.5 mg/mL MTT reagent (SERVA, GmbH, Heidelberg, Germany) diluted in
respective cell culture media without fetal bovine serum (FBS) for 1 h at 37 ◦C. The formed formazan
crystals were dissolved in DMSO and the absorbance was measured using a Synergy HTX plate reader
(BioTech-Hungary, Budapest, Hungary) at 570 nm. All the experiments were repeated three times and
the data were analyzed by GraphPad Prism 7 software (GraphPad Software; San Diego, CA, USA).
3. Results and Discussion
3.1. Synthetic Studies
For the synthesis of D-ring-fused 5-aminopyrazoles, DHEA was used as a starting material.
Formylation at C-16 with ethyl formate in the presence of a strong base by the Claisen condensation and
the following acidification led to compound 1 [27], which can exist as equilibrating tautomers (1a–c) in
solution (Scheme 1). The predominance of one or the other forms is highly affected by the proticity
and polarity of the solvent; however, 1b—where enolization occurs on the formyl group—was found
to prevail in neutral organic medium based on NMR measurements [28]. Condensation reaction of 1
with hydroxylamine hydrochloride in EtOH in the presence of NaOAc resulted in the corresponding
oxime capable of ring-chain tauromerism. Thus, two additional cyclic tautomers (2d and 2e) can
contribute to the equilibrium besides the three open forms (2a–c) [29]. According to 1H and 13C NMR
(J-MOD) measurements, only one of the possible tautomers (2d) is present in dimethyl sulfoxide
(DMSO) solution in good agreement with previous studies, where the same form was evidenced by IR
and XRD in the solid-state [23].
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Treatment of 2 with KOH in MeOH at room temperature or below resulted in a β-ketonitrile
(3) as a mixture of two epimers in excellent yield via base-induced elimination of a water molecule
(Scheme 1). It is important to note, however, that (a,1,a)-type fragmentation can occur leading to a
D-seco-carboxylic acid (4) at higher temperatures or by using a stronger and/or excess base [30]. The 1H
NMR spectrum of compound 3 showed some duplicated proton peaks (16-H, 18-CH3) at different
chemical shifts and with different integrals, indicating the presence of two diastereomers in a ratio of
about 2:1. Furthermore, the peak shapes of the 16-H protons allowed us to identify the epimers; that
is, a triplet at 3.78 ppm (J = 9.3 Hz) was assigned for the 16β-CN derivative, while a doublet at 4.36
ppm (J = 8.7 Hz) was assigned for the 16α-CN isomer. The splitting and coupling constants of 16-H
signals corresponded to the dihedral torsion angles θ(H16,C16,C15,H15α) and θ(H16,C16,C15,H15β)
calculated based on the Karplus equation for the two stereoisomers of 3.
In the following, β-ketoester (3) was used for the synthesis of steroidal heteroaromatic
5-aminopyrazoles without separating the diastereomers, since the asymmetric center disappears
during the ring-closure step with arylhydrazines. For preliminary experiments, compound 3 and
phenylhydrazine hydrochloride (5a, 1.2 equiv.) were reacted in EtOH under MW irradiation at different
temperatures (80, 100, and 120 ◦C) for 5, 10, 15, and 20 min in a closed vessel and the progress of the
transformations was monitored by thin-layer chromatography (TLC). Of all the reaction conditions,
120 ◦C and 10 min were found to be optimal for the complete conversion of the starting material.
However, alkaline work-up was needed in this case to neutralize the reaction mixture; otherwise,
a certain amount of the desired product was lost with the aqueous phase due to its basic characteristic of
forming a HCl salt in the presence of an excess reagent. Alternatively, the MW-assisted transformation
could also have been carried out within 10 min in the presence of NaOAc (1.2 equivalent) to liberate the
binucleophilic reagent from its HCl salt, and the product (6a) was again obtained in excellent yield after
purification by column chromatography (Table 1, entry 1). The reaction of 3 with 5a was also performed
in refluxing EtOH for comparison. Conventional heating greatly lengthened the reaction time (12 h),
although the yield of the product (6a) was only slightly lower (85%) than in the MW-induced method.
In the 1H NMR spectrum of 6a with a phenyl (Ph) group directly attached to the pyrazole-N, the signals
of the aromatic protons were identified between 7.0 and 7.6 ppm with characteristic multiplicities,
while the singlet of 5′-NH2 appeared at around 5.0 ppm. According to the 13C NMR (J-MOD) spectra
of 6a, the negative signal of C-17 was found at around 170 ppm, consistent with the chemical shift of a
carbon in a pyridine-like environment (C = N) for similar pyrazole derivatives [6].
Table 1. Syntheses of D-ring-fused 5-amino-1-arylpyrazoles in the androstane series.
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1 5a Ph 6a 90
2 5b 4-CH3-C6H4 6b 89
3 5c 4-OMe-C6H4 6c 92
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The reaction is considered to involve a nucleophilic addition of the terminal nitrogen of the
arylhydrazine (5) to the carbonyl-C17 of 3 and subsequent dehydration to afford hydrazones, which then
undergo intramolecular ring-closure by the attack of the internal nitrogen on the nitrile carbon to provide
5-aminopyrazole 6 (Table 1) [14]. According to the proposed mechanism, the rate of both consecutive
reaction steps depends on the nucleophilicity of the reagent, which may be affected by the electron
demand of the substituent of the aromatic ring. Therefore, similar reactions of 3 were also performed
with para-substituted phenylhydrazine hydrochlorides (5b–h) in order to investigate the possible
substituent effect on the heterocyclizations. All MW-assisted reactions were carried out in a closed vessel
under identical conditions at 120 ◦C for 10 min. However, due to the elevated temperature and efficient
heat transfer provided by the MW conditions, a marked substituent effect could not be observed, except
for the reaction of 3 with para-nitrophenylhydrazine (5h) where the strong electron-withdrawing effect
of the NO2 group hampered the ring-closure to occur, and substantially decreased the yield of the
desired product 6h (Table 1, entry 8). However, complete conversion was also achieved in this case
by prolonging the reaction time to 20 min. The novel D-ring-condensed arylpyrazoles (6b–h) were
purified by column chromatography and characterized by NMR spectroscopy similarly to 6a.
3.2. Proton Dissociation Processes
As expected, compounds 6a–h have a poor aqueous solubility, according to UV-visible
spectrophotometric titrations. This fact means that lower concentrations had to be used to monitor
their proton dissociation processes, thus titrations were done under highly diluted conditions (10 µM)
in aqueous solution (containing 1% (v/v) EtOH). Compounds displayed absorption bands in the UV
region mostly due to pi-pi* transitions of the benzene ring and the pyrazole moiety. Representative
UV spectra for 6a are shown in Figure 2a. Deprotonation of the compounds resulted in characteristic
spectral changes, namely the λmax was increased (Table 2) and the absorbance decreased upon this
process. Notably, precipitate appeared while increasing the pH (from pH > 5) in all cases except the
nitro derivative 6h (pH > 3.5). Thus, spectra recorded in the pH range 1.8–5 (or 3.5) were used for the
calculations. The changes revealed one deprotonation step in the studied pH range. Computed molar
spectra for the HL+ and L ligand species of 6a are shown in Figure 2b.
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Figure 2. (a) UV spectra recorded for 6a at various pH values; (b) Calculated molar absorbance spectra
for the HL+ and L species of 6a. {c = 10 µ ; l 2 cm; t = 25 ◦C; I = 0.1 M (KCl); 1% (v/v) EtOH/H2O}.
Proton dissociation constants (pKa) wer ined by the deconvoluti n of th measured
spectra and re collected in Table 2. The determine a alues are attributed o the pyrazole N2H+
moiety, and its eprotonati results in the formation of the neutral L form with fairly limited solubility.
The pKa values vary by the different substituents of the benzene ring. The methoxy (6b), methyl (6c),
and fluorine groups (6d) resulted in similar or somewhat lower pKa value of the pyrazole nitrogen
(Table 2, entries 2–4) compared with that of the reference compound 6a (entry 1). On the other hand,
the presence of the chloro (6e), bromo (6f), cyano (6g) and nitro substituents (6h) decreased the pKa
value significantly due to their strong electron-withdrawing effect (Table 2, entries 5–8).
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In summary, all steroidal heterocycles (6a–h) are neutral (L) at pH 7.4 based on the determined pKa
values. Moreover, they are highly lipophilic and characterized by a poor water solubility. The lipophilic
character and membrane permeability are important drug properties as they strongly affect the passage
through biological membranes. Thus, we attempted to determine the logD7.4 and permeability values
by the traditional shake-flask method in n-octanol/H2O (buffered aqueous solution, pH 7.40) and by
the parallel artificial membrane permeability assay (PAMPA), respectively. All these compounds were
found to be so lipophilic that logD7.4 and permeability data could not be obtained experimentally, since
practically the total quantity of the compounds remained in the n-octanol phase after the partitioning,
which hindered the concentration determination in the aqueous phase. Therefore, logD7.4 values were
estimated for the compounds by the means of the MarvinSketch software [31] (Table 2). The predicted
logD7.4 values indicated that the aforementioned compounds are strongly lipophilic, which should be
accompanied by very good membrane permeability.
Table 2. Proton dissociation constants (pKa) of the compounds determined by UV-visible titrations,
λmax values (nm) of the ligand species in HL+ and L forms and logD7.4 (= logP) values predicted by the
MarvinSketch software [31]. {t = 25 ◦C; I = 0.1 M (KCl); 1% (v/v) EtOH/water}.
Entry Compd. R pKa λmax (nm) of HL+ λmax (nm) of L logD7.4 (Predicted)
1 6a H 3.97 ± 0.03 243 249 +4.31
2 6b CH3 3.37 ± 0.03 243 252 +4.77
3 6c OMe 3.78 ± 0.06 240 244 +4.05
4 6d F 3.56 ± 0.04 242 2212 1 +4.45
5 6e Cl 2.00 ± 0.03 245 - 1 +4.83
6 6f Br 2.07 ± 0.06 247 - 1 +5.10
7 6g CN <1.8 ~260 ~276 +4.12
8 6h NO2 2.13 ± 0.09 248, 289 236, 334 +4.26
1 The spectrum of L has no characteristic absorption band in the studied wavelength range.
3.3. Pharmacological Studies
In order to screen the cancer cell-specific antiproliferative effect of the synthesized D-ring-fused
steroidal 5-aminopyrazoles (6a–h), various human cancerous cell lines, namely MCF-7, PC-3, A549,
HeLa and U2Os cells and MRC-5 noncancerous fibroblasts were treated with the test compounds in
5 µM concentration for 72 h. A heat map (Figure 3) was constructed based on the obtained viability
data (Supplementary Material, Table S1). It was found that compound 6g showed the most prominent
antiproliferative activity and proved to be efficient on all the tested cancer cells. The other compounds
exerted minor or fair cytotoxic effects and their cancer-specific antiproliferative features were much
less pronounced than that of 6g.
Based on the primary screen, compound 6g was selected from the compound library. Then its
cytotoxicity was evaluated more precisely on all aforementioned noncancerous and cancerous cell
lines. The IC50 values of 6g, especially those obtained on PC-3, HeLa, and U2Os cells are notably
lower compared to that on MRC-5 noncancerous fibroblasts, despite falling in the same order of
magnitude (Table 3, Supplementary Material, Figure S1a). Among all cancer cell lines, A549 showed
the lowest, whereas U2Os displayed the highest sensitivity to 6g treatment. As a positive control,
the same set of cell lines was treated with the ‘gold standard’ cisplatin for 72 h, and the IC50 values
were determined likewise (Table 3, Supplementary Material, Figure S1b). As expected, cisplatin
exhibited strong antiproliferative activity at fairly low concentrations on the tested cell types, whereas
compound 6g was effective at concentrations in the µM range. It is well-known that a number of
cancer cells exhibit resistance towards cisplatin treatment. In line with previous reports [32], we also
observed that PC-3 cell lines displayed resistance to the applied cisplatin, indicated by the high IC50
value. Interestingly, compound 6g effectively inhibited the proliferation of PC-3 cells, and the IC50
value of compound 6g obtained on this particular cell line was comparable to its IC50 values on
other tested cancer cells. No resistance toward molecule 6g could be observed upon our experiments.
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Apart from cancer cell resistance, the sensitivity of noncancerous cells can also cause complications.
In fact, noncancerous MRC-5 cells were more sensitive to cisplatin treatment than cancerous cells.
This was clearly demonstrated by the IC50 value for cisplatin on fibroblasts, being one magnitude
smaller (37 nM) than any of its IC50 values on cancerous cells. However, noncancerous fibroblasts did
not manifest higher sensitivity toward compound 6g, yielding an advantageous feature for this test
molecule over cisplatin.
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Figure 3. Primary antiproliferative effect of the steroidal D-ring-fused 5-aminopyrazoles on different
cancerous cell lines and on MRC-5 fibroblasts represented as heat map {compound = 5 µM; 72 h
incubation time}. Control represents the viability of cells receiving no treatment.
Table 3. IC50 (±SD) values of compound 6g and of cisplatin assessed on noncancerous MRC-5 cells and
on various cancer cell lines.
Compd. IC50
MRC-5 MCF-7 PC-3 A549 HeLa U2Os
6g (µM) 8.9 ± 1.1 6.2 ± 1.0 4.9 ± 1.1 7.9 ± 1.0 4.0 ± 1.0 3.5 ± 1.0
Cisplatin (nM) 37.72 ± 1.2 338.5 ± 1.1 902 ± 1.6 369.8 ± 1.2 254.5 ± 1.2 342.8 ± 1.2
4. Conclusions
The main aim of the present study was to develop a multistep synthetic route for the preparation
of novel D-ring-fused 5-aminopyrazoles (6a–h) in the androstane series involving a MW-assisted
heterocyclization of a steroidal β-ketonitrile (3) with different arylhydrazines (5a–h) as the key step.
Although the cyclization of β-ketonitriles with monosubstituted hydrazines usually needs a long
reaction time (12–72 h), the applied MW-induced protocol allowed the high yield of the desired
products within 10–20 min. The ring-closures were found not to be significantly influenced by
the electron demand of the substituent R present on the aromatic ring of the reagents, with the
only exception of the strong electron-withdrawing NO2-group. Proton dissociation processes of the
heterocycles were investigated by UV-visible spectrophotometric titrations in aqueous solution, as pKa
of a bioactive compound is a key physicochemical parameter affecting the pharmacokinetic properties.
Moreover, based on its value, the actual protonation state can be established at physiological pH.
Furthermore, the antiproliferative activity of the 5-aminopyrazoles was screened in vitro on different
human cancer cell lines, along with a noncancerous cell line. Compound 6g was selected for further
studies as among the tested molecules this was the most potent in inhibiting the proliferation of the
tested cancer cells, including cisplatin-resistant PC-3 prostate cancer cells. These results indicate that
D-ring-fused 5-amino-1-arylpyrazoles can be considered as promising synthetic platforms for obtaining
new active steroidal derivatives. Additionally, their biological significance, in particular those of the
Appl. Sci. 2020, 10, 229 12 of 13
CN-group-containing compounds, can be broadened to novel cancer therapy approaches. It is worth
noting that the syntheses of similar derivatives with improved water solubility are in progress and the
results will be published in the near future.
Supplementary Materials: The following are available online at http://www.mdpi.com/2076-3417/10/1/229/s1,
1H NMR and 13C NMR spectra of the synthesized compounds, Table S1: Mean ± SD values of primary growth
inhibitory screen (given as cell viability) used for heat map construction, Figure S1: Representative cell viability
curves to determine growth inhibition and IC50 values following treatments with (a) compounds 6g or (b) cisplatin
on different cell lines.
Author Contributions: Conceptualization, É.F.; M.K. and É.A.E.; Chemical synthesis and optimization
experiments, G.M. and Á.B.; Pharmacological studies, M.K.G. and D.I.A.; UV-visible spectrophotometric
titrations, M.A.M.; Structural analysis, G.M.; Formal analysis and interpretation of data, Á.B., D.I.A. and
M.A.M.; Methodology, resources, supervision, É.F.; M.K. and É.A.E.; Writing—original draft preparation, G.M.
and M.K.G.; Writing—review and editing, É.F.; M.K. and É.A.E. All authors have read and agreed to the published
version of the manuscript.
Funding: This research received no external funding.
Acknowledgments: This work was supported by the National Research, Development and Innovation
Office-NKFIA through projects GINOP-2.3.2-15-2016-00038 and FIKP program TUDFO/47138-1/2019-ITM. M.A.M.
thanks the support of Visegrád Scholarship Program. The research of G.M. was supported by the National Talent
Program of the Hungarian Ministry of Human Capacities.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Tantawy, M.A.; Nafie, M.S.; Elmegeed, G.A.; Ali, I.A.I. Auspicious role of the steroidal heterocyclic derivatives
as a platform for anti-cancer drugs. Bioorg. Chem. 2017, 73, 128–146. [CrossRef] [PubMed]
2. Stulov, S.V.; Misharin, A.Y. Synthesis of steroids with nitrogen-containing substituents in ring D (Review).
Chem. Heterocycl. Compd. 2013, 48, 1431–1472. [CrossRef]
3. Frank, É.; Schneider, G. Synthesis of sex hormone-derived modified steroids possessing antiproliferative
activity. J. Steroid Biochem. Mol. Biol. 2013, 137, 301–315. [CrossRef] [PubMed]
4. Ansari, A.; Ali, A.; Asif, M. Shamsuzzaman. Review: Biologically active pyrazole derivatives. New J. Chem.
2017, 41, 16–41. [CrossRef]
5. Karrouchi, K.; Radi, S.; Ramli, Y.; Taoufik, J.; Mabkhot, Y.; Al-aizari, F.A.; Ansar, M. Synthesis and
pharmacological activities of pyrazole derivatives: A review. Molecules 2018, 23, 134. [CrossRef]
6. Baji, Á.; Kovács, F.; Mótyán, G.; Schneider, G.; Wölfling, J.; Sinka, I.; Zupkó, I.; Ocsovszki, I.; Frank, É.
Investigation of pH and substituent effects on the distribution ratio of novel steroidal ring D- and A-fused
arylpyrazole regioisomers and evaluation of their cell-growth inhibitory effects in vitro. Steroids 2017, 126,
35–49. [CrossRef]
7. Kovács, D.; Wölfling, J.; Szabó, N.; Szécsi, M.; Schelz, Z.; Zupkó, I.; Frank, É. Synthesis of novel 17- (4’-formyl)
pyrazolylandrosta-5,16-dienes and their derivatives as potent 17α-hydroxylase/C17,20-lyase inhibitors or
antiproliferative agents depending on the substitution pattern of the heteroring. Eur. J. Med. Chem. 2016,
120, 284–295. [CrossRef]
8. Li, J.; Zhao, X.; Li, L.; Yuan, Z.; Tan, F.; Shi, B.; Zhang, J. Design, synthesis and cytotoxic activity of a novel
series of steroidal phenylpyrazoles. Steroids 2016, 107, 45–54. [CrossRef]
9. Mótyán, G.; Mérai, L.; Kiss, M.A.; Schelz, Z.; Sinka, I.; Zupkó, I.; Frank, É. Microwave-assisted synthesis
of biologically relevant steroidal 17-exo-pyrazol-5’-ones from a norpregnene precursor by a side-chain
elongation/heterocyclization sequence. Beilstein J. Org. Chem. 2018, 14, 2589–2596. [CrossRef]
10. Mótyán, G.; Gopisetty, M.K.; Kiss-Faludy, R.E.; Kulmány, Á.; Zupkó, I.; Frank, É.; Kiricsi, M. Anti-cancer
activity of novel dihydrotestosterone-derived ring A-condensed pyrazoles on androgen non-responsive
prostate cancer cell lines. Int. J. Mol. Sci. 2019, 20, 2170. [CrossRef]
11. Frank, É.; Mucsi, Z.; Zupkó, I.; Réthy, B.; Falkay, G.; Schneider, G.Y.; Wolfling, J. Efficient approach to
androstene-fused arylpyrazolines as potent antiproliferative agents. Experimental and theoretical atudies
of aubstituent effects on BF3-catalyzed intramolecular [3 + 2] cycloadditions of olefinic phenylhydrazones.
J. Am. Chem. Soc. 2009, 131, 3894–3904. [CrossRef]
Appl. Sci. 2020, 10, 229 13 of 13
12. Mótyán, G.; Zupkó, I.; Minorics, R.; Schneider, G.; Wölfling, J.; Frank, É. Lewis acid-induced intramolecular
access to novel steroidal ring D-condensed arylpyrazolines exerting in vitro cell-growth-inhibitory effects.
Mol. Divers. 2015, 19, 511–527. [CrossRef]
13. Mótyán, G.; Kovács, F.; Wölfling, J.; Gyovai, A.; Zupkó, I.; Frank, É. Microwave-assisted stereoselective
approach to novel steroidal ring D-fused 2-pyrazolines and an evaluation of their cell-growth inhibitory
effects in vitro. Steroids 2016, 112, 36–46. [CrossRef]
14. Aggarwal, R.; Kumar, V.; Kumar, R.; Singh, S.P. Approaches towards the synthesis of 5-aminopyrazoles.
Beilstein J. Org. Chem. 2011, 7, 179–197. [CrossRef]
15. Aggarwal, R.; Kumar, S. 5-Aminopyrazole as precursor in design and synthesis of fused pyrazoloazines.
Beilstein J. Org. Chem. 2018, 14, 203–242. [CrossRef]
16. Marizzoni, M.; Marcelli, G.; Carotti, A. N-Aryl-5-aminopyrazole: A versatile architecture in medicinal
chemistry. Mini-Rev. Med. Chem. 2015, 15, 272–299. [CrossRef]
17. Hu, F.; Szostak, M. Recent developments in the synthesis and reactivity of isoxazoles: Metal catalysis and
beyond. Adv. Synth. Catal. 2015, 357, 2583–2614. [CrossRef]
18. De Oliveira Silva, A.; McQuade, J.; Szostak, M. Recent advances in the synthesis and reactivity of isothiazoles.
Adv. Synth. Catal. 2019, 361, 3050–3067. [CrossRef]
19. Borthakur, M.; Barthakur, M.G.; Boruah, R.C. Microwave promoted one-pot synthesis of novel A-ring fused
steroidal dehydropiperazines. Steroids 2008, 73, 539–542. [CrossRef]
20. Shekarrao, K.; Kaishap, P.P.; Gogoi, S.; Gogoi, S.; Boruah, R.C. A facile synthesis of steroidal D-ring fused
pyrazolo[1,5-a]pyrimidines. Tetrahedron Lett. 2014, 55, 5251–5255. [CrossRef]
21. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and
cytotoxicity assays. J. Immunol. Methods 1983, 65, 55–63. [CrossRef]
22. Mótyán, G.; Molnár, B.; Wölfling, J.; Frank, É. Microwave-assisted stereoselective heterocyclization to novel
ring D-fused arylpyrazolines in the estrone series. Molecules 2019, 24, 569. [CrossRef]
23. Brückner, K.; Irmscher, K.; von Werder, F.; Bork, K.H.; Metz, H. Reactions with 16-methylene- and
16-hydroxymethylene-17-oxo steroids. Chem. Ber. 1961, 94, 2897–2909. [CrossRef]
24. Zékány, L.; Nagypál, I. Computational Methods for the Determination of Stability Constants; Plenum Press: New
York, NY, USA, 1985.
25. Enyedy, É.A.; Hollender, D.; Kiss, T.J. Lipophilicity of kinetically labile metal complexes through the example
of antidiabetic Zn(II) and VO(IV) compounds. J. Pharm. Biomed. Anal. 2011, 54, 1073–1081. [CrossRef]
26. Chen, X.; Murawski, A.; Patel, K.; Crespi, C.L.; Balimane, P.V. A novel design of artificial membrane for
improving the PAMPA model. Pharm. Res. 2008, 25, 1511–1520. [CrossRef]
27. Huang, Y.; Liu, M.; Meng, L.; Feng, P.; Guo, Y.; Ying, M.; Zhu, X.; Chen, Y. Synthesis and antitumor evaluation
of novel hybrids of phenylsulfonylfuroxan and epiandrosterone/dehydroepiandrosterone derivatives. Steroids
2015, 101, 7–14. [CrossRef]
28. Oda, T.; Sato, R.; Sato, Y. The hydrogenation of α-hydroxymethylene-ketone derivatives to
α-hydroxymethyl-ketone derivatives with a cell-free system of Streptomyces cinereocrocatus. Chem.
Pharm. Bull. 1989, 37, 502–505. [CrossRef]
29. Jones, P.R. Ring-Chain Tautomerism. Chem. Rev. 1963, 63, 461–487. [CrossRef]
30. Mótyán, G.; Kádár, Z.; Kovács, D.; Wölfling, J.; Frank, É. Regio- and stereoselective access to novel
ring-condensed steroidal isoxazolines. Steroids 2014, 87, 76–85. [CrossRef]
31. MarvinSketch (Version 16.12.12.0, Calculation Module Developed by ChemAxon). 2016. Available online:
http://www.chemaxon.com/products/marvin/marvinsketch/ (accessed on 9 July 2019).
32. Gumulecz, J.; Balvan, J.; Sztalmachova, M.; Raudenska, M.; Dvorakova, V.; Knopfova, L.; Polanska, H.;
Hudcova, K.; Ruttkay-Nedeczky, B.; Babula, P.; et al. Cisplatin-resistant prostate cancer model: Differences
in antioxidant system, apoptosis and cell cycle. Int. J. Oncol. 2014, 44, 923–933. [CrossRef]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
